Birnavirus Oncolytic Therapy for Cancer Stem Cell Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective, inexpensive, easy-to-administer, and stable options, particularly for targeting cancer stem cells resistant to conventional treatments, and there is a need for new therapeutic approaches beyond existing oncolytic viruses.
Innovation Solution
The use of birnaviruses, specifically the Infectious Bursal Disease Virus (IBDV) strain R903/78, which promotes immunogenic cell death and immunomodulation, is explored as a treatment or prevention method for cancer, combining apoptosis induction and interferon activation to target cancer cells effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-cancer therapies are used, then some cancer types can be treated, but they are ineffective against certain cancers such as liver, lung, brain and pancreatic cancer
Solution Approach 1:
The patent employs oncolytic viruses with broad spectrum activity that can target multiple cancer types including liver, lung, brain and pancreatic cancers. The viral vectors are designed to infect and replicate in diverse tumor cells, providing a universal therapeutic approach that overcomes the limitation of conventional therapies being effective only for specific cancer types.
Solution Approach 2:
The patent utilizes the ability of oncolytic viruses to change their biological parameters - they can selectively replicate within tumor cells, induce immunogenic cell death, and stimulate anti-tumor immune responses. These dynamic parameter changes allow the therapy to adapt to different cancer types and microenvironments, improving both reliability and versatility across various malignancies.
2Reliability
If oncolytic viruses are used to target cancer cells, then selective targeting and immune system stimulation are achieved, but the therapy complexity increases
Solution Approach 1:
The oncolytic viruses are engineered to autonomously perform multiple functions: they selectively infect cancer cells through specific receptor recognition, replicate within tumor cells to cause lysis, and simultaneously stimulate the immune system. This self-service capability reduces the need for external intervention and complex delivery systems, thereby managing therapy complexity while maintaining high selective targeting capability.
Solution Approach 2:
The patent combines multiple therapeutic mechanisms into a single oncolytic virus platform - direct cytolytic activity, immunogenic cell death induction, and immune system activation are merged into one therapeutic agent. This consolidation simplifies the overall therapy approach compared to using separate treatments for each mechanism, reducing device complexity while preserving reliable selective targeting.
3Productivity
If high doses of birnavirus are administered, then treatment efficacy is improved, but safety concerns may arise
Solution Approach 1:
The birnavirus is engineered with local quality characteristics that enable it to specifically target and replicate in cancer cells while sparing normal cells. The virus exhibits different biological properties in tumor versus healthy tissue - high replication and cytolytic activity in cancer cells, but minimal activity in normal cells. This localized differential activity allows high effective doses to be delivered to tumors without causing harmful side effects in healthy tissues.
Solution Approach 2:
The patent converts the potential harm of high-dose virus administration into a benefit by exploiting the selective vulnerability of cancer cells. The high viral replication that could be harmful in normal cells is instead directed specifically at cancer cells, where it produces therapeutic benefit through oncolysis and immune activation. The harmful potential is thus transformed into therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The birnavirus-based approach demonstrates safety and efficacy in treating a broad range of cancers, including glioma, head and neck cancers, and multiple myeloma, with oral administration showing promise, even at high doses, without significant side effects, and can be used in monotherapy or combination with other anti-cancer therapies.
Implementation Method 1
promotes immunogenic cell death and immunomodulation
Implementation Method 2
combining apoptosis induction and interferon activation to target cancer cells effectively
Implementation Method 3
combining apoptosis induction and interferon activation to target cancer cells effectively
Data Source
AI summary
The present invention relates to a birnavirus for use in the treatment or prevention of cancer. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment or prevention of cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment or prevention of cancer.